title: Sildenafil and ocular perfusion.
authors.forename: W E
authors.initials: WE
authors.lastname: Sponsel
authors.forename: G
authors.initials: G
authors.lastname: Paris
authors.forename: S S
authors.initials: SS
authors.lastname: Sandoval
authors.forename: D K
authors.initials: DK
authors.lastname: Sanford
authors.forename: J M
authors.initials: JM
authors.lastname: Harrison
authors.forename: W R
authors.initials: WR
authors.lastname: Elliott
authors.forename: Y
authors.initials: Y
authors.lastname: Trigo
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000328:Adult; D005123:Eye / Q000098:blood supply*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D011673:Pulsatile Flow / Q000187:drug effects; D011687:Purines; D012039:Regional Blood Flow / Q000187:drug effects; D000068677:Sildenafil Citrate; D013450:Sulfones
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases